A randomised, double-blind, placebo-controlled crossover study to assess the efficacy of a single dose of 100 mg of VRP700 by inhalation in reducing the frequency and severity of cough in adult patien

This was a single-center, randomized, double-blind crossover study that examined the efficacy of a single inhaled dose of VRP700 versus placebo for reducing cough frequency in 20 patients with IPF with chronic cough. The primary endpoint was the number of coughs in the 4-hour period following the end of nebulized treatment, measured using the Vitalograph VitaloJAK device.